<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 163 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page162.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=163">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 163 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 163</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=163"><img src="../thumb/163.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>132 / 2020-04                                                        Cardio-Vascular Agents - 7.7.2
   Contraindications: Other HMG-CoA reduct. inhibit. hypersens., ac./  hypothyroid./heredit.musc.disords or hist.thereof/ hist of musc.toxic.  Adults:
   chron.liv.dis., unexplain. persist. elev.ser.transaminas., pregn., breast   with another HMG-CoA reduct. inhibit.or fibrate/alcoh.abuse/&gt;70 yrs.,   Hypercholesterolaem: 10 mg/day as sngl.even. dos. Reduc.if LDL-
   feed., porphyr., women of child bear.potent., safety & effic. in pts.und.   situat. where incr.plasma lev.poss./concom.fibrat., withdr. in ac.ser.  cholesterol falls bel.1,94 mmol/L or tot.plasma chol.lev.fall bel.3,6
   18 yrs.& in ren.impairm.not est.  condit.suggest.of myopathy/pre-dispos.to ren.fail.developm.second.  mmol/L. If necess. adjust dos.at interv.of not less than 4 wks. up to
   Side effects: CNS effs., periph. polyneuropathy, paraesthes., vis.  to rhabdomyolys., concom.fusid.acid not recomm., excess. alcoh.con-  max.80 mg/day as sngl.even.dos.
   disturbs., GI disturbs., pancreatit., skin rash, alopec., abnorm.uri-  sumpt., liv.dis.hist., LFT prior to init./ 3 mnths aft., discont./reduc.ther.  Cor.heart dis: Init. 20 mg/day as sngl.even.dos.
   nat., sex.dysfunct., fatig., mass gain., non card.& card.chest pain,   if ser. transaminas. lev.&gt; 3xULN, treat.underly. hypothyroid./ nephrot.  If necess.adjust dos.at interv.of not less than 4 wks. up to max.80 mg/
   arthralg., myalg., musc. cramps/-weakn., rhabdomyolys., myopathy,   syndr.bef.init.ther., incr. system. expos.in Asian pts., concom.protease   day as sngl.even.dos.
   myosit., isol.tend. disords. poss.with rupt., hypersens.reacts.incl.   inhibits. in HIV infect.pts., diab.mellit., monit.INR with warfar.., lact.  Contraindications: Other HMG-CoA reduct. inhibit. hypersens., ac./
   angio-oed. & lupus like syndr., jaund., hepatit., fulmin. hepat.necros.,   intol., admin.antacid 2 hrs.aft. ther., paed.exper.limit.to small no.of   chron.liv.dis., unexplain. persist.elev.ser.transaminas., safety pregn.&
   upper resp.infect., rhinit.  childr.8 yrs.& old. with homozyg.famil.hypercholesterolaem., var.   lactat./ porphyr.not est., women of child bear. potent., safety & ef-
   Special precautions: Act.metabol.fetotox. & teratogen.in rats,   protease inhibits.concom.with ritonavir.  fic.in paed.pts.not est.
   admin.1 hr.bef./4 hrs.aft. cholestyramine/colestipol, monit.INR bef.  Interactions: Incr. plasma.conc.with OATP1B1/ BCRP inhibits., AUC   Side effects: GI disturbs., pancreatit., anaem., neutropen., skin
   init./reg. dur.& with dos. adjustm.of concom.anticoag.ther., 10 mg/  on avg.7xhigh.with concom. ciclosporin, Cmax & AUC 2x incr.with gem-  rash, alopec., myalg., musc. cramps, myopathy, myosit., rhabdo-
   day recomm.with concom.cyclospor.titrat. with caut., not suit.for   fibrozil, incr. AUC with ezetemibe, incr.system.expos.& adverse effs.  myolys., CNS effs., fatig., paraesthes., periph.neuropathy, hypers-
   hypercholesterolaem.due to elev. HDL cholester., combinat.with   with var. protease inhibit.in combinat. with ritonavir, antacids cont.Mg   ens. reacts.incl.angio-oed., mass gain., abnorm. liv.funct.test., incr.
   fibrat.not recomm., eval.risk vs.benef.in childr.bef.puberty, discont.   & Al decr.plasma conc., incr.ethinyl oestrad.& norgestrel AUC with   ser.creatin.kinase.
   if rise in transaminase lev.persist./incr.3x or more of upper limit of   oral contracept.& simil.eff.with HRT cannot be excl.  Special precautions: Act.metabol.fetotox.& teratogen. in rats,
   norm., liv.dis.hist., heavy alcoh.ingest., pt.to report.unexplain.sympts.  ROSVATOR, Ranbaxy [P/S]  max.dos.10 mg/day recomm. with concom.cyclospor./fibrates/lipid
   indicat. myopathy, discont.ther.if myopathy diagnos./ suspect., con-  Rosuvastatin.  low.niacin dos., monit.INR bef.init./reg.dur.& with dos. adjustm. of
   com.nicotin.acid., incr.myopathy report. with other statins combin.  Indications: Diet.adjunct.in prim. hypercholesterolaem. /mix.dyslipi-  concom.anticoag.ther., admin.1 hr.bef. /4 hrs. aft.cholestyramine, sev.
   with cytochrome P450 metabol.inhibit., ren.impairm., hypothyroid.,   daem./isolat. hypertriglyceridaem.(incl.Fredrickson Type IIa, IIb & IV   ren.impairm., subst. alcoh. ingest., liv.dis.hist., predisposit.to ren.fail.
   statin/ fibrate assoc.musc.toxic hist., person./ heredit. musc.disord.  and exclud.heterozyg.familial hypercholesterolaem.) when respons.  second. to rhabdomyolysis, monit.liv.funct.bef.init. ther. & period.dur.
   hist., meas.CK lev.in pts.over 70 yrs./ predispos.fact., do not init.ther.  to diet & exerc. inadeq., homozygous familial hypercholesterolaem.   ther.x1 yr.aft.last dos.elev., discont. if rise in transaminase lev.per-
   or discont. ther.if CK lev.&gt;5xULN.  either alone or as adjunct.to diet & other lipid low.treatm.  sist./incr.3x or more of upper limit of norm., pt.to report. unexplain.
   Drug interactions: Cholestyramine/colestipol decr. bioavail., incr.  (S4) TABS. 45/7.5/0955, 0956, 0957, 0958  sympts.indicat.myopathy, discont.ther.if myopathy diagnos./suspect.,
   plasma lev.with meds.that inhibit. cytochrome P450 isoenzyme CY-  719249-001: 5 mg, 30, R87,98  concom.cyclospor./ itra-/ketoconazole /erythro-/clarithromycin /HIV
   P3A4 (e.g.cyclospor./itra-/ketoconazole/erythro-/ clarithromycin/ HIV   719251-001: 10 mg, 30, R135,67  prot. inhibit.& nefazodone not recomm.,discont. ther. tempor.in pts.
   prot.inhibit.& nefazodone) incr.myopathy risk, digox.lev.incr.  719252-001: 20 mg, 30, R208,59  receiv.cyclospor.if system. azole-antifung.ther.reqd.
                                                              Drug interactions: Incr.plasma lev.with meds. that inhibit.cyto-
   ROSUVASTATIN UNICORN, (Unicorn) Sandoz [P/S]  719253-001: 40 mg, 30, R248,32  chrome P450 isoenzyme CYP3A4 (e.g.ciclospor./itra-/ketoconazole/
   Rosuvastatin.                Dosage: Init.& contin.cholest.low.diet bef.& dur. treatm. Dos.range   erythro-/clarithromycin/HIV prot.inhibit.& nefazodone) incr.myopathy
   Indications: CV event risk reduct.in adult pts.with incr.risk of ath-  5-40 mg once dly. Recomm. start.dos: 5 mg once dly. Indiv.accord.  risk, incr.myopathy risk.with other meds.known to cause myopathy
   erosclerot.CV dis.bas.on CV dis.risk mark. to reduc.risk of non-fatal   to ther.goal & pt.respons. Maj.pts.control.on 10 mg dos. Dos. adjustm.  (e.g fibrates & niacin), digox.lev.incr., anticoag.eff.of coumar. antico-
   stroke/non-fatal MI & need for arter.revascularisat., prim. hyper-  can be made at 2-4 wk interv.in necess.  ags.poss.incr., cholestyramine decr.bioavail.
   cholesterolaem./ mix.dyslipidaem./isolat. hypertriglyceridaem. incl.  Prim.hypercholesterolaem./mix.dyslipidaem. & isol.hyper-
   Fredrickson Type IIa/IIb/& IV & heterozygous familial-& non-familial   triglyceridaem: Recomm.start.dos: 5 mg once dly. also for pts.  SIMVACOR, Pharma Dynamics [P/S]
   hypercholesterolaem. as adjunct.to diet & exerc. when respons.in-  of Asian ancestry. Start. dos.of 20 mg may be consid.in sev. hy-  Simvastatin.
   adeq., prim. dysbetalipoproteinaem (Fredrickson Type III), reduc. tot.  percholesterolaem.  Indications: In combinat with diet to decr.elev. ser.tot.cholester.&
   cholester.& LDL-C in homozygous familial hypercholesterolaem.alone   Homozygous familial hypercholesterolaem: Start.recomm.  LDL-cholester.in prim. hypercholesterolaem./heterozyg.familial hy-
   or as adjunct. to diet & other lipid low.treatm.  dos: 20 mg once dly.  percholesterolaem./mix.hyperlipidaem.when respons.to diet & other
   Childr.10-17 yrs: Tot.cholester./LDL-C & APO B reduct. in heterozy-  Concom.ther.: Addit.effic.shown.with concom. fenofibrate in lower.  nonpharmacolog.meas. inadeq., reduc.risk of tot.mortal.by reduc.cor-
   gous familial hypercholesterolaem.  triglycerid.& may incr. HDL-C lev. with niacin. Bile acid sequestrant.   on. death/reduc.risk of non-fat.MI/reduc.risk of myocard. revasculat.
   (S4) TABS. 46/7.5/0307, 0308, 0309, 0310  or ezetimibe can be used. Max.dos.10 mg/ day when used with pro-  proced.& slow.coron. artheroscleros. progress in pts.with coron.heart
   3000400-001: 5 mg, 30, R87,98  tease inhibits. Init. ther.with 5 mg once dly.& do not exceed 20 mg   dis.& hypercholesterolaem. unrespons.to diet.
   3000401-001: 10 mg, 30, R135,69  once dly with concom. gemfibrozil.  (S4) TABS, 35/7.5/0237,0238, 39/7.5/0132
   3000402-001: 20 mg, 30, R208,62  Contraindications: Other HMG-CoA reduct. inhibit.hypersens.,   700519-002: 10 mg, 30, R34,50
   3000403-001: 40 mg, 30, R248,36  act.liv.dis., concom.ciclospor., myopathy, not recomm.in childr.  700520-002: 20 mg, 30, R35,70
   Dosage: Cholester.low.diet in place. Indiv.accord. to ther.goal &   due to insuffic. data on safety & effic., safety in pregn.& lactat.  708463-001: 40 mg, 30, R36,60
   pt.respons. Recomm.start.dos: 5 mg once dly. Dos.range: 5-40 mg   not est., lact.intol.  Dosage: Cholestr.low.diet bef.init.& dur.ther.
   once dly. Maj. pts. control.on 10 mg dos. Dos.adjustm.can be made   Side effects: Myalg., myopathy, rhabdomyolys., hypersens.incl.angi-  Hypercholesterolaem: 10 mg/day as sngl.dos.in even. Reduc.dos.
   at 2-4 wk interv.            oed., incr.ser.gluc.lev., headache, dizzin., CNS effs., GI disturbs., abd.  if LDL-cholester.lev.falls below 1,94 mmol/L or tot.plasma cholester.
   Prim.hypercholesterolaem.incl.heterozygous familial hyper-  pain, pancreatit., jaund., hepatit., incr.hepat.transamin., skin reacts.,   lev.falls below 3,6 mmol/L
   cholesterolaem./mix. dyslipidaem./ dysbetalipoproteinaem.&   arthralg., proteinur., asthen., glycaem. contr.worsen., cognit.impairm.  Coron.heart dis: Init. 20 mg/day as sngl.dos.in even.
   isol. hypertriglyceridaem: Recomm.start.dos: 5 mg once dly. Pts.  Special precautions: Consid.40 mg admin.only in sev. hypercho-  Dosage adjustm: Adjust dos.if reqd.at interv.of not less than 4 wks.
   of Asian ancestry & pts. requir.a small.LDL-C reduct.to achiev.  lesterolaem.& high CV risk who do not achieve treatm.goal on 20 mg   to a max.of 80 mg/day as sngl. dos. in even. In sev.ren.insuffic.imple-
   treatm.target: 5 mg start.dos.recomm. Start.dos.of 20 mg may be   treatm./alt. ther., women of childbear.potent.to use adeq. contracept.,   ment dos. above 10 mg/day with caut.
   cons. in sev.hypercholesterolaem.  meas.CK lev./discont.ther.if myopathy diagn./suspect., incr.myosit.&   Concom.ther: Bile acid sequestr: Admin.1 hr. bef./ 4 hrs.aft.
   Homozygous familial hypercholesterolaem: Start.recomm.  myopathy incid. report.in pts.on other HMG-CoA reduct.inhibit.tog.   cholestyramine. Cyclosporine, fibrates or niacin: Max.recomm.
   dos: 20 mg once dly.         with ciclospor./fibr.acid derivats.incl.gemfibrozil/ nicotin. acid/azole   dos: 10 mg/day
   Heterozygous familial hypercholesterolaem. in childr.10-17   antifung.& macrolide antibiot., predispos. myopathy fact.such ac.ren.  Contraindications: Ac./chron.liv.dis., unexplain. persist.ser.transam-
   yrs: Usual dos.range: 5-20 mg once dly. Titr.to achieve treatm.goal.   impairm./ advanc. age/hypothyroid./heredit.musc.disord. hist./ musc.  inas.elev., pregn.& lactat., porphyr., female pts.of child-bear.potent.,
                                                              safety & effic.in paed.pts.not est., concom.meds.inhibit. P450 CYP3A4
                                toxic.hist.with anoth.statin/fibrate, alcoh.abuse &/chron.liv.dis.hist.,
   Safety & effic. of dos.&gt; 20 mg not stud.
   Concom.ther.: Addit.effic.shown with concom. fenofibrate in lower.  situat.where plasma lev.incr.may occur, condit.suggest.of myopathy/   e.g. cyclospor./itraconazole/ ketoconazole, erythromyc/clarithromyc/
                                                              HIV proteas. inhibit.& nefazodone not recomm.
                                pre-dispos.to ren.fail.developm. second.to rhabdomyolys., monit.INR
   triglycerid.& may incr. HDL-C lev. with niacin. Bile acid sequestrant.
   or ezetimibe can be used. Max.dos.of 10 mg/day when used with   with warfar., cons. benef./risk with concom.fenofibrat., sev.ren./   Side effects: GI disturbs., bld.dyscras., skin reacts., alopec., my-
                                                              alg., musc.cramps, myopathy, myositis, rhabdomyolys., CNS effs.,
                                hepat.funct impairm., incr.plasma conc.in Asian pts., liv.enzym.monit.
   protease inhibits.
   Init.ther.with 5 mg once dly.& do not exceed 20 mg once dly with   bef.end & at 12 wks.follow. ther. init.& any dos.elev./per.thereaft.,   paraesthes., periph. neuropathy, hypersens. reacts.incl.lupus-like
                                interr.ther. in case of ser.liv.injury with clinic.sympt.&/ hyperbiliru-
   concom.gemfibrozil.                                        syndr., mass gain.
   Contraindications: Act.liv.dis., sev.ren.impairm., concom. ciclospor.,   binaem./jaund., Type 2 diab., incr. fast. ser.gluc.lev., concom.agents   Special precautions: Incr.myopathy risk with concom.meds. caus.
                                decr.activ.lev.of ster. horm.such as ketoconazole/spironolactone/ ci-
   myopathy, safety in pregn.& lactat. not est. women of childbear.po-  metidine, ren.funct.assessm.dur.follow up of pts. treat.with 40 mg   myopathy, determine INR when init.ther.& monit.dur.early ther.with
                                                              concom. coumar.anticoags., substant.alcoh.consumpt., liv. dis.hist.,
   tent.not using. adeq.contracept. 40 mg also: Predispos. myopathy/
   rhabdomyolys.fact.eg. mod.ren. impairm./ hypothyroid./heredit.musc.  dos., concom.lopinavir/ ritonavir.  predisposit.to develop.ren. fail.second.to rhabdomyolys., sev.ren.im-
                                                              pairm., LFT recomm. prior to init.ther.& period.until 1 yr.aft.last dos.
                                Drug interactions: Poss.INH incr.with concom. warfarin, AUC on
   disords or hist. thereof/prev.musc.toxic.hist.with anoth.HMG-CoA
   reduct. inhibit.or fibrate/alcoh.abuse/ situat. where incr.plasma lev.  aveg.7xhigh.with concom. ciclosporin, C max & AUC 2x incr.with gem-  elev., discont.in case of persist.ser.transamin. lev. incr., monit.for myo-
                                                              pathy & discont.if myopathy occurs/suspect., outweigh benef.-risk
                                fibrozil, incr. system.expos.& adverse effs.with var. protease inhibit.in
   poss.occur/Asian pts./ concom. fibrat.
   Side effects: Freq: Diab.mellit., headache, dizzin., diarrh., abdom.  combinat.with ritonavir, antacids contain Mg & Al decr.plasma conc.,   with concom. immunosuppress./fibrates/lipid.low. niacin. dos.& do
                                enhanc. skelet.musc.eff.with niacin, decr.AUC (o-t) & C max with eryth-
                                                              not exceed dos of 10 mg/day, withdr.tempor.in pts receiv.cyclospor.
   pain, constip., N&V, asthen. Less freq: Thrombocytopen., hypersens.
   reacts. incl.angioed., polyneuropathy, memory loss, angina pect.,   romycin, incr.ethinyl oestrad.& norgestrel AUC with oral contracept.&   if system. azole derivat.antifung.reqd.
                                                              Drug interactions: Meds.inhibit.P450 CYP3A4 poss.incr.plasma
                                simil.eff. with HRT cannot be excl., rhabdomyolys.report. with con-
   chest pain, hypertens., periph.oed., dyspn., rhinit., sinusit., cough,   com.ezetimibe, incr.AUC & C max with liponavir/ ritonavir.  lev., digoxin lev.incr., anticoag. eff.of coumar.anticoags.incr., bile
   pancreatit., gastrit., dyspeps., prurit., rash, urticar., myalg., rhabdomy-  acid sequestr. decr.bioavail.
   olys., myopathy, haematur., gynaecomast., flu syndr. Freq.unknown:   SANDOZ PRAVASTATIN, Sandoz [P/S]
   Depress., periph.neuropathy., sleep disturbs., jaund., hepatit., Stev.-  Pravastatin sod.  STORWIN, Zentiva [P/S]
   Johns.syndr., arthralg., rhabdomyolys. assoc.with ren.funct.impairm.,   Indications: In combinat.with diet to decr.elev. ser.tot.cholesterol &   Rosuvastatin.
   proteinur., oed., incr.hepat.transaminas./CK  LDL cholesterol in prim. hypercholesterolaem./heterozyg.familial hy-  Indications: Adjunct.to diet & exerc.when respons. inadeq in prim.
   Warnings and special precautions: Consid. 40 mg admin.only in   percholesterolaem./mix.hyperlipidaem.when respons.to diet/ other   hypercholesterolaem.( Type IIa excl.heterozyg.familial hypercholes-
   sev.hypercholesterolaem.& high CV risk who do not achiev.treatm.  non pharmacolog.meas. alone not adeq., coron.heart dis.& hypercho-  terolaem.)/ mix. dyslipidaem.(Type IIb)/ hypertriglyceridaem. Type IV),
   goal on 20 mg treatm./alt.ther., women of childbear. potent. to use   lesterolaem. unrespons.to diet, to reduc. tot. mortality risk by reduc.  homozygous familial as adjunct. to diet & other lipid low.treatm./if
   adeq.contracept., ren.funct.monit.& specialist supervis.dur.40 mg   coron.death/reduc.risk of non-fat.MI/ reduc. risk of undergoing myo-  these treatm.not appropr.
   dos., monit.CK lev.if S&S suggest.of myopathy pres.& discont.ther if   card. revascularizat.proced. & slow.progress.of coron. atheroscleros.  (S4) TABS. 45/7.5/0502, 0503, 0504
   myopathy is diagn./susp., incr.myosit.& myopathy incid. report.in pts.  (S4) TABS, A39/7.5/0300, 0301, 0302  719194-001: 10 mg, 30, R152,09
   on other HMG-CoA reduct.inhibit.tog.with ciclospor./fibrates/ fenofi-  705901-001: 10 mg, 30, R205,65  719195-001: 20 mg, 30, R229,67
   brate/gemfibrozil/nicotin.acid/azole antifung. & macrolide antibiot.,   705902-001: 20 mg, 30, R264,86  719197-001: 40 mg, 30, R279,33
   do not init.ther if CK lev.&gt;5xULN but re-meas.aft.5-7 days to re-con-  705903-001: 40 mg, 30, R309,41  Dosage: Init.& contin.diet ther.bef.& dur.treatm. Indiv.ther.accord.to
   firm result, do not meas.CK aft.stren.exerc./if alternat.cause of CK   Dosage: In combinat.with cholesterol-low.diet. Is effect.alone or in   ther.goal & pt.respons. Admin. low.dos. provid.ther.benef.
   incr.poss., predispos. myopathy/ rhabdomyolys. fact.eg.ren.impairm./   combinat.with bile acid sequestrants.  Recomm.start.dos: 5 mg (ie.half 10 mg tab) once dly. Dos.adjustm.to</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page162.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page158.html">158</a>&nbsp;&nbsp;&nbsp;<a href="page159.html">159</a>&nbsp;&nbsp;&nbsp;<a href="page160.html">160</a>&nbsp;&nbsp;&nbsp;<a href="page161.html">161</a>&nbsp;&nbsp;&nbsp;<a href="page162.html">162</a>&nbsp;&nbsp;&nbsp;<a href="page163.html">163</a>&nbsp;&nbsp;&nbsp;<a href="page164.html">164</a>&nbsp;&nbsp;&nbsp;<a href="page165.html">165</a>&nbsp;&nbsp;&nbsp;<a href="page166.html">166</a>&nbsp;&nbsp;&nbsp;<a href="page167.html">167</a>&nbsp;&nbsp;&nbsp;<a href="page168.html">168</a>
             </td>
             <td width="35%"><a href="page164.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page164.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
